Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016652 · ClinicalTrials.gov registry record · NA
Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients
A NA study of Presbyopia, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 8
- Study locations
NCT01016652: Completed NA study of Presbyopia, sponsored by Johnson & Johnson Vision Care.
NCT01016652 is a NA study of Presbyopia that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 49 participants, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01016652, a NA study of Presbyopia, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of a multi-focal contact lens on symptomatic patients.
Primary Outcome
The Contact Lens User Experience (CLUE) Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response, with scores ranging from 0-120.
Conditions Studied
Interventions
- DEVICE etafilcon A multifocal contact lens
- DEVICE etafilcon A Contact Lens
Study Locations (8)
Missouri
- - Blue Springs
- - Lake Ozark
Arkansas
- - North Little Rock
Ohio
- - Warren
Pennsylvania
- - Kittanning
Rhode Island
- - Warwick
South Dakota
- - Chamberlain
Vermont
- - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-10-01 |
| Est. Completion | 2009-12-01 |
| Phase | NA |
What the finished NCT01016652 record still lists
NCT01016652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Presbyopia appearing as the primary indexed condition, and to 2 interventions - of which etafilcon A multifocal contact lens is the first listed.
NCT01016652 lists 8 locations in 7 states (Missouri, Arkansas, Ohio).
Frequently Asked Questions
What is clinical trial NCT01016652 about?
NCT01016652 is a clinical study titled "Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients". The purpose of this study is to evaluate the effect of a multi-focal contact lens on symptomatic patients.
What is the current status of trial NCT01016652?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2009-10-01. Estimated completion is 2009-12-01.
What conditions does trial NCT01016652 study?
This clinical trial studies the following conditions: Presbyopia.
What interventions are being tested in trial NCT01016652?
The interventions under investigation include: etafilcon A multifocal contact lens (DEVICE), etafilcon A Contact Lens (DEVICE).
Who is sponsoring clinical trial NCT01016652?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01016652 being conducted?
This trial has 8 study locations across Arkansas, Missouri, Ohio, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01016652's enrollment target sits among peer trials
49 28th of 38 higher than 11 of 38 other Presbyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Presbyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
-
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
RECRUITING · NA
-
Presbyopic Wear Experience With Multifocal Lenses Compared to Single Vision Lenses and Reading Glasses
RECRUITING · NA
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
ACTIVE NOT RECRUITING · NA
-
Clinical Evaluation of a Small Aperture Extended Depth of Focus Intraocular Lens
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI